zabdeno
janssen-cilag international n.v. - recombinant adenovirus type 26 (ad26) encoding the glycoprotein (gp) of the ebola virus zaire (zebov) mayinga strain - hemorraagiline palavik, ebola - vaktsiinid - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.
octreotide csc süstelahus
gp-pharm s.a. - oktreotiid - süstelahus - 100mcg 1ml 1ml 5tk
octreotide csc süstelahus
gp-pharm s.a. - oktreotiid - süstelahus - 50mcg 1ml 1ml 5tk
octreotide csc süstelahus
gp-pharm s.a. - oktreotiid - süstelahus - 500mcg 1ml 1ml 5tk
irinotecan csc infusioonilahuse kontsentraat
gp-pharm s.a. - irinotekaan - infusioonilahuse kontsentraat - 20mg 1ml 15ml 1tk; 20mg 1ml 5ml 1tk; 20mg 1ml 2ml 1tk; 20mg 1ml 25ml 1tk
oxaliplatin csc infusioonilahuse pulber
gp-pharm s.a. - oksaliplatiin - infusioonilahuse pulber - 5mg 1ml 50mg 1tk; 5mg 1ml 100mg 1tk
gemcitabine csc 1000 mg infusioonilahuse pulber
gp-pharm s.a. - gemtsitabiin - infusioonilahuse pulber - 1000mg 1tk
gemcitabine csc 200 mg infusioonilahuse pulber
gp-pharm s.a. - gemtsitabiin - infusioonilahuse pulber - 200mg 1tk
ervebo
merck sharp & dohme b.v. - rekombinantse vesikulaarset stomatiiti viirus (tüvi, indiana), mille kustutamise ümbrik glükoproteiini asendada zaire ebolavirus (tüvi kikwit 1995) pinna glükoproteiin - hemorraagiline palavik, ebola - vaktsiinid - ervebo is indicated for active immunization of individuals 1 year of age or older to protect against ebola virus disease (evd) caused by zaire ebola virus. kasutada ervebo peab olema kooskõlas ametlike soovitustega.
mvabea
janssen-cilag international n.v. - recombinant modified vaccinia ankara bavarian nordic virus encoding the: ebola virus zaire (zebov) mayinga strain glycoprotein (gp); ebola virus sudan gulu strain gp; ebola virus taï forest strain nucleoprotein and the marburg virus musoke strain gp - hemorraagiline palavik, ebola - vaktsiinid - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.